全文获取类型
收费全文 | 3248041篇 |
免费 | 244677篇 |
国内免费 | 5679篇 |
专业分类
耳鼻咽喉 | 44732篇 |
儿科学 | 106237篇 |
妇产科学 | 89729篇 |
基础医学 | 473797篇 |
口腔科学 | 89775篇 |
临床医学 | 295981篇 |
内科学 | 627497篇 |
皮肤病学 | 72990篇 |
神经病学 | 260100篇 |
特种医学 | 121672篇 |
外国民族医学 | 905篇 |
外科学 | 487575篇 |
综合类 | 72089篇 |
现状与发展 | 15篇 |
一般理论 | 1197篇 |
预防医学 | 257230篇 |
眼科学 | 75840篇 |
药学 | 238774篇 |
11篇 | |
中国医学 | 6859篇 |
肿瘤学 | 175392篇 |
出版年
2021年 | 25750篇 |
2019年 | 26578篇 |
2018年 | 36902篇 |
2017年 | 27784篇 |
2016年 | 31374篇 |
2015年 | 35232篇 |
2014年 | 50039篇 |
2013年 | 75067篇 |
2012年 | 102804篇 |
2011年 | 109782篇 |
2010年 | 64994篇 |
2009年 | 61548篇 |
2008年 | 102224篇 |
2007年 | 108719篇 |
2006年 | 109900篇 |
2005年 | 106672篇 |
2004年 | 102237篇 |
2003年 | 98051篇 |
2002年 | 94708篇 |
2001年 | 150345篇 |
2000年 | 154098篇 |
1999年 | 129231篇 |
1998年 | 37784篇 |
1997年 | 33437篇 |
1996年 | 33493篇 |
1995年 | 31630篇 |
1994年 | 29187篇 |
1993年 | 27413篇 |
1992年 | 99446篇 |
1991年 | 96570篇 |
1990年 | 93875篇 |
1989年 | 90431篇 |
1988年 | 83283篇 |
1987年 | 81299篇 |
1986年 | 76230篇 |
1985年 | 73162篇 |
1984年 | 54931篇 |
1983年 | 46673篇 |
1982年 | 28113篇 |
1979年 | 50097篇 |
1978年 | 35576篇 |
1977年 | 29636篇 |
1976年 | 28263篇 |
1975年 | 30008篇 |
1974年 | 36236篇 |
1973年 | 34532篇 |
1972年 | 32541篇 |
1971年 | 30476篇 |
1970年 | 28352篇 |
1969年 | 26810篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Willemijn A K M Windt Atsua Tahara Alex C A Kluppel Dick de Zeeuw Robert H Henning Richard P E van Dokkum 《Journal of the renin-angiotensin-aldosterone system》2006,7(4):217-224
INTRODUCTION: Vasopressin, mainly through the V1a-receptor, is thought to be a major player in the maintenance of hyperfiltration. Its inhibition could therefore lead to a decrease in progression of chronic renal failure. To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I). MATERIALS AND METHODS: After 5/6 nephrectomy, early intervention was performed between week 2 and 10 thereafter with the V1a-receptor-selective antagonist (VRA, 10 mg/kg/day, n=10), enalapril (ACE-I, 10 mg/kg/day, n=9), or vehicle (n=8). Late intervention was performed in another group between week 6 and 12 with VRA (10 mg/kg/day, n=7), lisinopril (ACE-I, 5 mg/kg/day, n=7), or vehicle (n=7). RESULTS: In early intervention, proteinuria and focal glomerulosclerosis were significantly decreased by VRA compared to vehicle (44+7% and 59+8% respectively). ACE-I significantly decreased proteinuria (67+7%) and a trend towards a decrease in focal glomerulosclerosis was observed (30+18%). In late intervention, VRA did not decrease proteinuria and focal glomerulosclerosis compared to vehicle (21+20% and 0%, respectively), ACE-I significantly lowered proteinuria (92+2%) and a focal glomerulosclerosis (69+1%) lowering trend was observed. CONCLUSION: These results indicate that VRA may protect against early progression of renal injury after 5/6 nephrectomy, whereas its effectiveness seems limited in established renal damage. 相似文献
992.
993.
994.
995.
Robin L. Bissinger MSN RNC NNP Cheryl A. Carlson MS RNC NNP 《Newborn and Infant Nursing Reviews》2006,6(2):87
Surfactant, a complex substance containing specific proteins and phospholipids, is essential for gas exchange in the lungs. Research shows that surfactant not only lowers surface tension, but also plays a role in host defense. Surfactant replacement therapy is a cornerstone in the treatment of respiratory distress syndrome in premature infants. New information on endogenous surfactant composition including surfactant apoproteins has led to advances in the surfactant replacement products currently available. Because of the success of surfactant deficiency treatment in neonates, surfactant replacement therapy has been studied in both the pediatric and adult population for the treatment of other respiratory disorders. This article describes the composition, metabolism, and function of endogenous surfactant and other uses of surfactant replacement therapies in neonates. 相似文献
996.
Targeted silencing of disease-associated genes by synthetic short interfering RNA (siRNA) holds considerable promise as a novel therapeutic strategy. However, unmodified siRNA can be potent triggers of the innate immune response, particularly when associated with delivery vehicles that facilitate intracellular uptake. This represents a significant barrier to the therapeutic development of siRNA due to toxicity and off-target gene effects associated with this inflammatory response. Here we show that immune stimulation by synthetic siRNA can be completely abrogated by selective incorporation of 2'-O-methyl (2'OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex. These noninflammatory siRNA, containing less than 20% modified nucleotides, can be readily generated without disrupting their gene-silencing activity. We show that, coupled with an effective systemic delivery vehicle, 2'OMe-modified siRNA targeting apolipoprotein B (apoB) can mediate potent silencing of its target mRNA, causing significant decreases in serum apoB and cholesterol. This is achieved at therapeutically viable siRNA doses without cytokine induction, toxicity, or off-target effects associated with the use of unmodified siRNA. This approach to siRNA design and delivery should prove widely applicable and represents an important step in advancing synthetic siRNA into a broad range of therapeutic areas. 相似文献
997.
998.
999.
1000.